Adynxx closes patient enrolment in Phase II trial of post-surgical pain treatment brivoligide

US-based biotechnology firm Adynxx has completed patient enrolment in a Phase II trial (ADYX-004) of its lead product candidate, brivoligide (AYX1), for reducing acute pain and preventing chronic pain following total knee replacement surgery.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news